Conceptual approaches to modulating antibody effector functions and circulation half-life

KO Saunders - Frontiers in immunology, 2019 - frontiersin.org
Antibodies and Fc-fusion antibody-like proteins have become successful biologics
developed for cancer treatment, passive immunity against infection, addiction, and …

Biomaterial-based strategies for maxillofacial tumour therapy and bone defect regeneration

B Tan, Q Tang, Y Zhong, Y Wei, L He, Y Wu… - International journal of …, 2021 - nature.com
Issues caused by maxillofacial tumours involve not only dealing with tumours but also
repairing jaw bone defects. In traditional tumour therapy, the systemic toxicity of …

An immunogenic cell death-related classification predicts prognosis and response to immunotherapy in head and neck squamous cell carcinoma

X Wang, S Wu, F Liu, D Ke, X Wang, D Pan… - Frontiers in …, 2021 - frontiersin.org
Immunogenic cell death (ICD) has been classified as a form of regulated cell death (RCD)
that is sufficient to activate an adaptive immune response. Accumulating evidence has …

PD/1-PD-Ls checkpoint: insight on the potential role of NK cells

S Pesce, M Greppi, F Grossi, G Del Zotto… - Frontiers in …, 2019 - frontiersin.org
The identification of inhibitory NK cell receptors specific for HLA-I molecules (KIRs and
NKG2A) provided the molecular basis for clarifying the mechanism by which NK cells kill …

Controlled drug delivery systems for oral cancer treatment—current status and future perspectives

F Ketabat, M Pundir, F Mohabatpour, L Lobanova… - Pharmaceutics, 2019 - mdpi.com
Oral squamous cell carcinoma (OSCC), which encompasses the oral cavity-derived
malignancies, is a devastating disease causing substantial morbidity and mortality in both …

[HTML][HTML] Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1

Z Yin, M Yu, T Ma, C Zhang, S Huang… - … for immunotherapy of …, 2021 - ncbi.nlm.nih.gov
Exosomes, as the main group of extracellular vesicles, are biologically active lipid-bilayer
vesicles that are naturally released from different types of normal or tumor cells. These …

Tumor microenvironment and immune-related therapies of head and neck squamous cell carcinoma

Y Qin, X Zheng, W Gao, B Wang, Y Wu - Molecular Therapy-Oncolytics, 2021 - cell.com
Head and neck squamous cell carcinomas (HNSCCs) are a type of common malignant
tumor, mainly manifesting as oropharyngeal, oral cavity, laryngopharyngeal …

Immune-related gene signature for predicting the prognosis of head and neck squamous cell carcinoma

Y She, X Kong, Y Ge, P Yin, Z Liu, J Chen, F Gao… - Cancer cell …, 2020 - Springer
Abstract Background Immune-related genes (IRGs) were linked to the prognosis of head
and neck squamous cell carcinoma (HNSCC). This study aimed to identify the effects of an …

Nutritional status as a predictive biomarker for immunotherapy outcomes in advanced head and neck cancer

M Guller, M Herberg, N Amin, H Alkhatib, C Maroun… - Cancers, 2021 - mdpi.com
Simple Summary Tumors of head and neck cancer are a heterogenous collection of
malignancies affecting the upper aerodigestive tract, the majority of which are head and …

Understanding the tumor microenvironment in head and neck squamous cell carcinoma

HS Rad, Y Shiravand, P Radfar… - Clinical & …, 2022 - Wiley Online Library
Head and neck squamous cell carcinoma (HNSCC) represents a heterogeneous group of
tumors. While significant progress has been made using multimodal treatment, the 5‐year …